<DOC>
	<DOCNO>NCT01042509</DOCNO>
	<brief_summary>The purpose study determine whether low-doses alemtuzumab rituximab combination effective treatment chronic graft-versus-host disease ( GVHD ) first-line therapy failure .</brief_summary>
	<brief_title>Combination Alemtuzumab Rituximab Low-doses Refractory Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description>Graft-versus-host disease ( GVHD ) common long-term complication patient underwent allogeneic transplantation . First-line therapy chronic GVHD base immunosuppressive agent ( usually cyclosporine corticosteroid ) achieve satisfactory response around 30 % patient . There ideal second-line treatment chronic GVHD ; however , numerous study publish therapeutic option alemtuzumab ( anti-CD52 ) rituximab ( anti-CD20 ) . This prospective , longitudinal , nonrandomized study alemtuzumab rituximab administer low-doses patient refractory chronic GVHD . Clinical response evaluate base Working Group Report 2006 , publish National Institute Health Consensus . Follow-up session weekly four week , every two week achieve response , finally every four week .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients chronic graftversushost disease . Patients 18 year old . Patients receive firstline treatment response ( failure ) , relapse steroid dependance . Patients active bacterial viral infection . Patients hematologic disease progression . Patient 's intolerance drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic Graft v Host Disease</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Low-dose</keyword>
	<keyword>Alemtuzumab rituximab combination</keyword>
</DOC>